ArticleDiscover oncology2025
TRIM19 enhances the chemosensitivity of endometrial cancer by regulating the TBX2/NRF2 axis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe chemoresistance occurrence significantly hinders the clinical treatment of advanced cancers, frequently leading to treatment failure. It was already known that tripartite motif protein 19 (TRIM19) enhances the chemosensitivity of human ovarian cancers. However, it remained unknown whether TRIM19 functions in the cisplatin resistance of endometrial cancer.
methodsThe establishment of cisplatin-resistant Ishikawa cell line (Ishikawa/DDP) was used to investigate the function of TRIM19 in cisplatin resistance. The mRNA levels of specific genes were assessed using real-time quantitative PCR, while protein levels were assessed through western blot analysis. Cell viability was evaluated using the cell counting kit-8. Overexpression of TRIM19 was achieved via TRIM19 plasmid transfection. Furthermore, protein interaction was investigated using an immunoprecipitation assay, and protein stability was evaluated using a cycloheximide chase assay.
resultsThe TRIM19 mRNA levels were dramatically reduced in cisplatin-resistant endometrial cancer tissues. Additionally, the mRNA and protein levels showed significant decreases in cisplatin-resistant Ishikawa cells. Overexpressing TRIM19 greatly enhanced the sensitivity of Ishikawa/DDP and parental cells to cisplatin, while effectively inhibiting T-Box transcription factor 2 (TBX2) protein and ring finger protein 2 (RNF2) signaling. Furthermore, TRIM19 was found to directly interact with TBX2 and facilitate its degradation in Ishikawa/DDP cells.
conclusionsTRIM19 effectively decreases TBX2 and NRF2 signaling by interacting with TBX2, consequently reversing the cisplatin-resistance of endometrial cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.